Programs for Biomedical Research, Division of Molecular Medical Science, Department of Dermatology, Graduate School of Biomedical Sciences, Hiroshima University, Kasumi, Minami-ku, Hiroshima, Japan.
Arch Dermatol Res. 2012 Oct;304(8):647-54. doi: 10.1007/s00403-012-1236-2. Epub 2012 Apr 19.
We previously reported that about 80 % of patients with atopic dermatitis and 60 % with cholinergic urticaria revealed type I allergy against sweat, by means of skin test against autologous sweat and/or histamine-release test for peripheral blood basophils with semi-purified sweat antigen. In this study, we developed an assay for sera to neutralize histamine-releasing activity of semi-purified sweat antigen. The semi-purified sweat antigen was pre-incubated with serially diluted sera for 30 min at 37 °C and was subjected to histamine-release activity. Histamine release-neutralization (HRN) activities were calculated by measuring the amount of histamine release from basophils in the presence or absence of semi-purified sweat antigen. Of 62 subjects, 39 showed positive histamine release (≥5 %) from their basophils in response to semi-purified sweat antigen, and sera of 34 out of 39 subjects (87.2 %) were also positive in HRN activity (≥10 %). The specificity of the HRN assay was 0.522. Moreover, HRN activities in sera were largely correlated with degrees of histamine release from peripheral blood basophils of the same donors in response to sweat antigen. To identify the substance that neutralizes histamine-release activity, we removed IgE and IgG from the sera of HRN (+) subjects by column chromatography. The HRN activities in 30 out of 42 sera were largely reduced by the removal of IgG. On the other hand, sera of four subjects lost HRN activity by the removal of IgE, suggesting that the majority of HRN (+) subjects have serum IgG against the sweat antigen as well as IgE bound to peripheral basophils. Thus, the HRN assay maybe useful for the screening of type I allergy against sweat antigen.
我们之前报道过,约 80%的特应性皮炎患者和 60%的胆碱能性荨麻疹患者通过自体汗液皮肤试验和/或用半纯化汗液抗原对周围血嗜碱性粒细胞进行组胺释放试验,显示出对汗液的 I 型过敏。在这项研究中,我们开发了一种用于检测血清中和半纯化汗液抗原的组胺释放活性的方法。半纯化的汗液抗原与血清在 37°C 下孵育 30 分钟,然后进行组胺释放活性检测。通过测量存在或不存在半纯化汗液抗原时嗜碱性粒细胞释放的组胺量,计算组胺释放中和(HRN)活性。在 62 名受试者中,有 39 名受试者的嗜碱性粒细胞对半纯化汗液抗原的组胺释放(≥5%)呈阳性,其中 39 名受试者中的 34 名(87.2%)的血清在 HRN 活性(≥10%)中也呈阳性。HRN 检测的特异性为 0.522。此外,血清中的 HRN 活性与同一供体外周血嗜碱性粒细胞对汗液抗原的组胺释放程度有很大的相关性。为了鉴定中和组胺释放活性的物质,我们通过柱层析从 HRN(+)受试者的血清中去除 IgE 和 IgG。在 42 份血清中,有 30 份的 HRN 活性在 IgG 去除后大大降低。另一方面,有 4 份血清的 HRN 活性在 IgE 去除后丧失,表明大多数 HRN(+)受试者具有针对汗液抗原的血清 IgG 和结合到外周嗜碱性粒细胞上的 IgE。因此,HRN 检测法可能有助于筛查针对汗液抗原的 I 型过敏。